MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX Orally Inhaled Migraine Drug

MAP Pharmaceuticals, Inc. MAPP today announced that it has submitted a New Drug Application to the United States Food and Drug Administration for LEVADEX orally inhaled migraine drug for the potential acute treatment of migraine in adults. According to the National Headache Foundation, approximately 30 million people in the United States suffer from migraine, a debilitating neurological disorder. Common symptoms of migraine include recurrent headaches, nausea, phonophobia and photophobia (sensitivity to light).